Nuzenio

I Studies

I Studies news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Ascletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - BioPharm InternationalBioPharm International · Mon, 10 Aug 2026 19:50:09 GMTAscletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR NewswirePR Newswire · Mon, 10 Aug 2026 11:00:00 GMTI study pathogens in sewage. Here’s how cyclospora could be getting into our food. - The Washington PostThe Washington Post · Sun, 09 Aug 2026 16:00:00 GMT

Timeline

Mon, 10 Aug 2026 19:50:09 GMTAscletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - BioPharm International
Mon, 10 Aug 2026 11:00:00 GMTAscletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR Newswire
Sun, 09 Aug 2026 16:00:00 GMTI study pathogens in sewage. Here’s how cyclospora could be getting into our food. - The Washington Post

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for I Studies.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.